Marvin L. White

Marvin L. White (chief executive) discloses dealings in 2 companies, chiefly Aptevo Therapeutics Inc. and Emergent BioSolutions Inc. In total, 16 filings cover trades dated from 20 May 2021 to 6 August 2026.

Sales make up the whole of the open-market record (1 sale, €160k). The rest of the record consists of 6 share grants and 9 option exercises.

Most recently, on 10 August 2026, the filings show an option exercise in Aptevo Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.